



HR0659

LRB104 20572 LAW 34055 r

1

HOUSE RESOLUTION

2

WHEREAS, More than 1 in 7 American adults are estimated to have chronic kidney disease (CKD), yet as many as 9 in 10 American adults with CKD do not know they have it; and

3

4

5

WHEREAS, At least 15% of Medicare beneficiaries have been diagnosed with CKD; and

6

7

WHEREAS, While the two most common causes of kidney disease are hypertension and heart disease, the third-leading cause of kidney disease is glomerulonephritis, often caused by rare, immune-mediated kidney diseases such as IgA nephropathy (IgAN); and

8

9

10

11

12

WHEREAS, Patients with glomerular diseases frequently advance to more costly and more debilitating later stages of kidney disease, including end-stage renal disease (ESRD), more quickly than patients with CKD in general, with estimates suggesting that rare kidney diseases make up 5 to 10% of CKD patients but account for approximately 25% of patients receiving treatment for kidney failure; and

13

14

15

16

17

18

19

WHEREAS, Patients often face delays in being diagnosed with IgAN and other immune-mediated kidney diseases, owing to the difficulty of the rare disease diagnostic odyssey, the

20

21

1 limited number of nephrology providers, and a lack of
2 awareness about the causes of kidney disease; and

3 WHEREAS, IgAN is twice as likely to appear in men as women,
4 can occur at any age but most likely strikes people in their
5 twenties and thirties, and is more common in Asians and white
6 people; and

7 WHEREAS, Kidney disease, including IgAN, presents a
8 significant burden to the health and lives of patients and
9 their families, and it also presents great challenges for the
10 healthcare system and healthcare costs of Illinois, with
11 estimates suggesting that patients with IgAN-attributed ESRD
12 have health costs exceeding \$63,000 per year; and

13 WHEREAS, While the federal Medicare program covers the
14 costs of dialysis for many patients with ESRD, 45% of ESRD
15 patients are dually eligible for Medicare and Medicaid, and
16 ESRD is a significant source of disability, with ESRD patients
17 employed at only one-fifth the rate of the general population;
18 and

19 WHEREAS, Kidney disease patients are entering a new era of
20 hope, including for rare diseases, with multiple drugs now
21 approved by the Food and Drug Administration to slow the
22 progression of CKD and multiple drugs approved to slow the

1 progression of IgAN specifically, including innovative
2 immunology-based therapies, and many more clinical trials are
3 underway for such products; and

4 WHEREAS, There is growing recognition that early
5 identification of kidney disease and rare kidney diseases,
6 including through broader screening of patients with low-cost
7 serum creatine blood tests and urine albuminuria creatine
8 ratio tests, can slow the progression of kidney disease and
9 prevent or delay ESRD, including in patients with
10 immune-mediated kidney diseases; and

11 WHEREAS, Designating an IgAN Awareness Day not only
12 increases awareness of kidney disease and glomerular diseases
13 but also supports efforts to improve policies that may
14 increase access to screening, diagnosis, and treatment for
15 kidney disease and to provide hope and inspiration to
16 patients, caregivers, and advocates working tirelessly to
17 advance awareness and better care for kidney disease;
18 therefore, be it

19 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
20 HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
21 we declare May 14, 2026 as IgAN Awareness Day in the State of
22 Illinois to increase awareness among patients, providers, and
23 policymakers of kidney disease and glomerular diseases, and

1 IgA nephropathy (IgAN) in particular.